J Clin Oncol 27(22):35843590 Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Over half our customers maintain joint health improvements for 3+ years
A., Dos Reis, M
Using a sterile syringe, draw 3 mL of Bacteriostatic Water
This content is for research and informational purposes only Common Research Doses Low (1.0mg / 1000mcg): Often utilized in conservative or localized skin remodeling trials, where lower concentrations effectively stimulate basal cell regeneration, elastin production, and fibroblast activity.[1] Mid (2.5mg / 2500mcg): The standard median dosage in systemic literature, frequently cited in in vivo protocols observing significant upregulation of angiogenesis, collagen synthesis, and the modulation of systemic inflammatory pathways.[2] High (5.0mg / 5000mcg): The upper threshold typically reserved for severe acute injury models, such as accelerated burn/scald wound healing, or larger animal models requiring a robust systemic delivery of the copper-peptide complex.[3] Frequency of Administration In experimental systemic protocols, GHK-Cu is most commonly administered once daily
